Outpatient Infusion Centers
Freestanding outpatient infusion centers delivering IV medications, biologics, and specialty drug therapies across oncology, rheumatology, neurology, and other chronic disease specialties.
- 5
- Verticals
Overview
Outpatient Infusion Centers deliver IV medications, biologics, and specialty drug therapies outside the hospital across oncology, rheumatology, neurology, and other chronic-disease specialties. The site-of-care shift from hospital outpatient departments to lower-cost freestanding and physician-office infusion is a powerful driver.
Demand is propelled by the growth of biologics and specialty infusibles and by payers steering infusion to lower-cost settings. It is a fast-consolidating, ancillary-rich category (often attached to specialty practices) attracting private equity. The federal data category is broad, covering other outpatient care centers as well.
Market snapshot
- Market size
- ~$70B
- Growth
- ~5.4%CAGR (2017–22, nominal)
- Companies
- ~10,809 firms
Mapped to a broad 'all other outpatient care centers' code, so ~$70B / ~10,800 firms captures more than infusion alone. Still, the site-of-care shift out of the hospital and specialty/biologic drug growth make freestanding infusion the fast-growing core (~5.4%/yr), and it is an active consolidation theme (Option Care, PE-backed platforms).
NAICS 621498. U.S. Census Bureau — 2022 Statistics of U.S. Businesses; U.S. Census Bureau — 2022 Economic Census. A broad residual code that captures other outpatient care beyond infusion centers.
Business model & economics
Revenue model
Drug margin plus infusion-service reimbursement
Key economics
- Recurring revenue
- High
- EBITDA margin
- Drug-margin- and site-of-care-driven
- Capex intensity
- Moderate
recurring chronic infusion
Characteristics
- Site-of-care shift to lower-cost freestanding infusion.
- Biologics and specialty infusibles drive growth.
- Often an ancillary attached to specialty practices.
M&A deal context
Who’s acquiring
- Infusion & specialty-care platforms
- Specialty MSO acquirers
- PE-backed consolidators
What’s driving deals
- Site-of-care shift to lower-cost infusion.
- Biologics and specialty-drug growth.
- Ancillary-driven specialty-practice consolidation.
Verticals in this segment
Find Outpatient Infusion Centers acquisition targets
Search Acquisera’s index for companies classified under Outpatient Infusion Centers (4.10.18) and build a targeted deal pipeline.
Search companies